BiotechTube

EIK1004-001 (IMP1707-001)

Phase 1/2Recruiting
0 watching 0 views this week💤 Quiet
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced Solid Tumors

Conditions

Advanced Solid Tumors

Trial Timeline

Apr 30, 2025 → Dec 1, 2028

NCT ID
NCT06907043

About EIK1004-001 (IMP1707-001)

EIK1004-001 (IMP1707-001) is a phase 1/2 stage product being developed by Eikon Therapeutics for Advanced Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06907043. Target conditions include Advanced Solid Tumors.

Hype Score Breakdown

Clinical
13
Activity
8
Company
5
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT06907043Phase 1/2Recruiting

Competing Products

20 competing products in Advanced Solid Tumors

See all competitors
ProductCompanyStageHype Score
AK-105AkesoPhase 1
32
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
33
EXS21546BiotrialPhase 1/2
33
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
25
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
NBTXR3NanobiotixPhase 1/2
36
pegfilgrastim + LY2523355Eli LillyPhase 1
33
SON-1010Sonnet BioTherapeuticsPhase 1
28
SON-1010Sonnet BioTherapeuticsPhase 1/2
36
BT1718Bicycle TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
IMC-18F1Eli LillyPhase 1
33
Tadalafil + GemcitabineEli LillyPhase 1
33
OKI-179OnKure TherapeuticsPhase 1
25
OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + RibociclibOnKure TherapeuticsPhase 1
25
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
41
LY3434172Eli LillyPhase 1
33
ACR-2316Acrivon TherapeuticsPhase 1
25
BBP-398LianBioPhase 1
25

Other Products from Eikon Therapeutics

BDB001Phase 2
47
EIK1001 + Pembrolizumab + Paclitaxel + Pemetrexed + CarboplatinPhase 2
47
IMP1734Phase 1/2
36
BDB001 (EIK1001) + AtezolizumabPhase 1
28